Browsing by Author "Ozdogu, H."
Now showing 1 - 20 of 32
- Results Per Page
- Sort Options
Item Age, Cytopenia at Diagnosis and History of Hypertension are associated with Stem Cell Mobilization Failures Among Patients with Multiple Myeloma(2015) Toprak, S. Kocak; Ozdogu, H.; Atilla, E.; Topcuoglu, P.; Uslu, A.; Kasar, M.; Gurman, G.; Ilhan, O.; Beksac, M.; 0000-0002-8902-1283; 0000-0003-3856-7005; AAD-5542-2021; AAL-3906-2021Item The Analysis of Patients with Poor Mobilization and Mobilization Failure: Can Rdw Be A Predictive Factor?(2016) Buyukkurt, N.; Aytan, P.; Kozanoglu, I.; Maytalman, E.; Yeral, M.; Gereklioglu, C.; Solmaz, S.; Korur, A.; Ozdogu, H.; Boga, C.; 0000-0002-0895-4787; 0000-0002-5268-1210; 0000-0001-5284-7439; 0000-0002-9580-628X; 0000-0002-8902-1283; 0000-0002-2553-7715; 0000-0002-9680-1958; AAE-1457-2021; AAE-1241-2021; F-6265-2019; ABC-4148-2020; AAD-5542-2021; AAD-6222-2021; AAE-3833-2019Item Autologous Hematopoietic Stem Cell Transplantation for Severe Refractory Crohn's Disease: A Case Report(2014) Ozdogu, H.; Serin, E.; Boga, C.; Kozanoglu, I.; Yeral, M.; Gereklioglu, C.; https://orcid.org/0000-0002-8902-1283; https://orcid.org/0000-0002-0138-6107; https://orcid.org/0000-0002-9680-1958; https://orcid.org/0000-0002-5268-1210; https://orcid.org/0000-0002-9580-628X; AAD-5542-2021; AAM-7281-2021; AAD-6222-2021; AAE-1241-2021; ABC-4148-2020Item Autologous Stem Cell Transplantation with High-Dose Mitoxantrone and Melphalan in Patients with Hodgkin and Non-Hodgkin Lymphoma: Long-Term Survival and Toxicity Data(2015) Gungor, B.; Yeral, M.; Adam, M.; Unsal, C.; Boga, C.; Ozdogu, H.; Koc, Y.; 0000-0002-9580-628X; 0000-0002-9680-1958; 0000-0002-8902-1283; ABC-4148-2020; AAD-6222-2021; AAD-5542-2021Item Comparable Outcomes Using A CMV-Matched or A Mismatched Donor for CMV Plus Patients Undergoing T-Replete Haplo-HSCT with PT-Cy for Acute Leukemia: A Study from IDWP and ALWP of the EBMT(2017) Cesaro, S.; Crocchiolo, R.; Tridello, G.; Knelange, N.; Van Lint, M. T.; Koc, Y.; Ciceri, F.; Gulbas, Z.; Tischer, J.; Afanasyev, B.; Bruno, B.; Castagna, L.; Blaise, D.; Mohty, M.; Irrera, G.; Diez-Martin, J. L.; Pierelli, L.; Pioltelli, P.; Arat, M.; Specchia, G.; Fagioli, F.; Ehninger, G.; Aljurf, M.; Carella, A. M.; Mikulska, M.; Nagler, A.; Styczynski, J.; Ozdogu, H.; https://orcid.org/0000-0002-8902-1283; AAD-5542-2021Item Comparable Outcomes Using A CMV-Matched or A Mismatched Donor for CMV Plus Patients Undergoing T-Replete Haplo-HSCT with PT-Cy for Acute Leukemia: A Study from IDWP and ALWP of the EBMT(2017) Cesaro, S.; Crocchiolo, R.; Tridello, G.; Knelange, N.; Van Lint, M. T.; Koc, Y.; Ciceri, F.; Gulbas, Z.; Tischer, J.; Afanasyev, B.; Bruno, B.; Castagna, L.; Blaise, D.; Mohty, M.; Irrera, G.; Diez-Martin, J. L.; Pierelli, L.; Pioltelli, P.; Arat, M.; Specchia, G.; Fagioli, F.; Ehninger, G.; Aljurf, M.; Carella, A. M.; Ozdogu, H.; Mikulska, M.; Nagler, A.; Styczynski, J.; 0000-0002-8902-1283; AAD-5542-2021Item Comparison of High and Intermediate Dose Etoposide with G-Csf Priming for Peripheral Blood Stem Cell Mobilization(2014) Buyukkurt, N.; Yeral, M.; Kozanoglu, I.; Kasar, M.; Unver, G.; Boga, C.; Ozdogu, H.; https://orcid.org/0000-0002-0895-4787; https://orcid.org/0000-0002-9580-628X; https://orcid.org/0000-0002-5268-1210; https://orcid.org/0000-0003-3856-7005; https://orcid.org/0000-0002-9680-1958; https://orcid.org/0000-0002-8902-1283; AAE-1457-2021; ABC-4148-2020; AAE-1241-2021; AAL-3906-2021; AAD-6222-2021; AAD-5542-2021Item Comparison of Ishage-Based Cd34 (+) Cell Enumeration Protocols on BD Facs Canto II and Attune Flow Cytometers(2014) Kozanoglu, I.; Unver, G.; Sariturk, C.; Baran, Y.; Yeral, M.; Boga, C.; Ozdogu, H.; https://orcid.org/0000-0002-5268-1210; https://orcid.org/0000-0002-4130-1059; https://orcid.org/0000-0002-9580-628X; https://orcid.org/0000-0002-9680-1958; https://orcid.org/0000-0002-8902-1283; AAE-1241-2021; AAS-7129-2021; ABC-4148-2020; AAD-6222-2021; AAD-5542-2021Item Comparison Of The Conditioning Regimens with or without TBI in Acute Lymphoblastic Leukemia Patients: Experience of A Single Center(2015) Yeral, M.; Boga, C.; Ozdogu, H.; Solmaz, S.; Korur, A. P.; Asma, S.; Kozanoglu, I.; 0000-0002-9580-628X; 0000-0002-5268-1210; 0000-0002-8902-1283; 0000-0002-9680-1958; ABC-4148-2020; AAE-1241-2021; AAD-5542-2021; AAD-6222-2021Item Demodocidosis Accompanying Acute Cutaneous Graft-Versus-Host Disease After Allogeneic Stem Cell Transplantation(2017) Aytan, P.; Yeral, M.; Gereklioglu, C.; Kocer, N.; Buyukkurt, N.; Kozanoglu, I.; Ozdogu, H.; Boga, C.; 0000-0002-2553-7715; 0000-0002-9580-628X; 0000-0002-5943-9283; 0000-0002-0895-4787; 0000-0002-5268-1210; 0000-0002-8902-1283; AAE-3833-2019; ABC-4148-2020; AAM-5436-2021; AAE-1457-2021; AAE-1241-2021; AAD-5542-2021; AAD-6222-2021Item Discovering Alternative Targets in Chronic Myeloid Leukemia (Cml): Determination of Expression Levels of Bioactive Sphingolipid Genes in Newly Diagnosed and Drug-Resistant Cml Patients(2015) Yandim, M. Kartal; Kozanoglu, I.; Ozdogu, H.; Piskin, O.; Ozcan, M. A.; Saydam, G.; Sahin, F.; Avcu, F.; Ural, A. U.; Unal, A.; Baran, Y.; 0000-0002-5268-1210; AAE-1241-2021Item Effectiveness of Fludarabine- and Busulfan-Based Conditioning Regimens in Patients With Acute Myeloblastic Leukemia: 8-Year Experience in a Single Center(2015) Kasar, M.; Asma, S.; Kozanoglu, I.; Maytalman, E.; Boga, C.; Ozdogu, H.; Yeral, M.; 0000-0001-5284-7439; 0000-0002-8902-1283; 0000-0001-5335-7976; 0000-0003-3856-7005; 0000-0002-9580-628X; 0000-0002-9680-1958; 0000-0002-5268-1210; 26036558; F-6265-2019; AAD-5542-2021; AAI-7831-2021; AAL-3906-2021; ABC-4148-2020; AAD-6222-2021; AAE-1241-2021Objective. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment for acute myeloblastic leukemia (AML). Because the conditioning regimen of busulfan plus cyclophosphamide carries significant risks of toxicity, we evaluated the factors affecting survival after fludarabine replacement instead of cyclophosphamide. Methods. The study included 55 patients who underwent allo-HSCT for AML and received busulfan, fludarabine, and antithymocyte globulin (ATG). Results. Forty-eight patients received a myeloablative regimen; 7 patients received a reduced-intensity conditioning regimen. The neutrophil and platelet engraftment times were 12 days (range 9 to 20) and 12 days (range 7 to 19), respectively. Graft-vs-host disease (GvHD) developed in 10% and 50% of the patients, respectively. Seven patients received donor lymphocyte infusion. Of them, 5 patients developed grade I or II GvHD, one grade IV GvHD. The median follow-up period was 20.6 months. The predicted progression-free survival (PFS) at 1 and 3 years after transplantation was 78% and 74%, respectively. The overall survival (OS) at 1, 3, and 5 years was 76%, 74%, and 62%, respectively. Treatmen-trelated mortality (infection in 1 patient, GvI-ID in 2 patients) occurred in 3 patients (5.5%). Multivariate analysis revealed that OS and PFS were not influenced by age, dose of busulfan or ATG, or presence of cytomegalovirus antigenemia. Acute GvHD and pretransplantation minimal residual disease positivity negatively affected the transplant outcome. The presence of active disease at the time of transplantation was found as an independent risk factor for AML. Conclusions. Busulfan- and fiudarabine-based conditioning regimens are effective for AML, and have acceptable toxicity, morbidity, and mortality.Item Expansion of Bone Marrow Derived Mesenchymal Stem Cells Using A Gmp Compliant Closed System Bioreactor and Quality Analysis of The Expanded Cells(2014) Kozanoglu, I.; Maytalman, E.; Bilir, P.; Unver, G.; Siber, C.; Boga, C.; Ozdogu, H.; https://orcid.org/0000-0002-5268-1210; https://orcid.org/0000-0001-5284-7439; https://orcid.org/0000-0002-9680-1958; https://orcid.org/0000-0002-8902-1283; AAE-1241-2021; F-6265-2019; AAD-6222-2021; AAD-5542-2021Item Expression Levels of Ceramide-Generating and Clearance Genes in Newly Diagnosed and Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia Patients: an Attempt To Find Novel Targets(2014) Yandim, M. Kartal; Kozanoglu, I.; Ozdogu, H.; Piskin, O.; Ozcan, M. A.; Saydam, G.; Sahin, F.; Avcu, F.; Ural, A. U.; Baran, Y.; https://orcid.org/0000-0002-5268-1210; https://orcid.org/0000-0002-8902-1283; AAE-1241-2021; AAD-5542-2021Item Expression Levels of Ceramide-Metabolising Genes in Newly Diagnosed and Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia (CML) Patients: The Discovery of Novel Targets in CML(2014) Yandim, M. Kartal; Kozanoglu, I.; Ozdogu, H.; Piskin, O.; Ozcan, M.; Saydam, G.; Sahin, F.; Avcu, F.; Ural, A.; Unal, A.; Baran, Y.; https://orcid.org/0000-0002-5268-1210; https://orcid.org/0000-0002-8902-1283; AAE-1241-2021; AAD-5542-2021Item Expression Levels of Jak/Stat Signaling Genes in Newly Diagnosed, Drug Sensitive and Resistant Chronic Myeloid Leukemia Patients(2015) Kiraz, Y.; Saydam, G.; Sahin, F.; Kozanoglu, I.; Ozdogu, H.; Piskin, O.; Ozcan, M. A.; Avcu, F.; Ural, A. U.; Unal, A.; Baran, Y.; 0000-0002-5268-1210; AAE-1241-2021Item Guillain-Barre Syndrome Associated with Parvovirus Infection After Allogeneic Hematopoietic Stem Cell Transplantation(2014) Yeral, M.; Boga, C.; Buyukkurt, N.; Kozanoglu, I.; Ozdogu, H.; Gereklioglu, C.; Goksel, B. Karakurum; https://orcid.org/0000-0002-9580-628X; https://orcid.org/0000-0002-9680-1958; https://orcid.org/0000-0002-0895-4787; https://orcid.org/0000-0002-5268-1210; https://orcid.org/0000-0002-8902-1283; https://orcid.org/0000-0003-2766-2277; ABC-4148-2020; AAD-6222-2021; AAE-1457-2021; AAE-1241-2021; AAD-5542-2021; AAE-2609-2021Item The Importance of External Quality Control for CD34 Positive Stem Cells(2015) Unver, G.; Kozanoglu, I.; Kaya, T.; Asar, E.; Maytalman, E.; Aydin, L.; Ozdogu, H.; Boga, C.; 0000-0001-5284-7439; 0000-0003-0483-2333; 0000-0002-5268-1210; 0000-0002-8902-1283; 0000-0002-9680-1958; F-6265-2019; AAC-5750-2022; L-6337-2019; AAE-1241-2021; AAD-5542-2021; AAD-6222-2021Item Is Active Invasive Fungal Infection A Contraindication For Allogeneic Stem Cell Transplantation in A Patient with Severe Aplastic Anemia?(2016) Solmaz, S.; Korur, A.; Gereklioglu, C.; Ulusan, S. N.; Boga, C.; Ozdogu, H.; https://orcid.org/0000-0002-9680-1958; https://orcid.org/0000-0002-8902-1283; AAD-6222-2021; AAD-5542-2021